PLYMOUTH MEETING, Pa., Sept. 1, 2021 /PRNewswire/ -- INOVIO , a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that Dr. J. Joseph Kim, President and CEO, will present at the following investor conferences in September: INOVIO is currently preparing to initiate a Phase 2 vaccine trial for INO-4700 in the Middle East where most MERS viral outbreaks have occurred. Introduction: VGX-3100, as a key R&D project of Oriental Strategy and INOVIO in the field of DNA immunotherapy, once approved, it will be the first in the world to be developed for the treatment of HPV-related precancerous lesions (cervical precancerous lesions, anal precancerous lesions) On March .
The company is focused on rapidly bringing to market precisely designed and delivered DNA medicines to potentially treat and protect people from serious and life-threatening diseases associated with HPV, cancer, and infectious diseases. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Inovio Pharmaceuticals . Live and archived versions of the virtual presentations will be available through the INOVIO Investor Relations Events .
CONTACTS: Media: Jeff Richardson, 267-440-4211, jrichardson@inovio.com Investors: Ben Matone, 484-362-0076, ben.matone@inovio.com * * * * Live and archived versions of the virtual presentations will be available through the INOVIO Investor Relations Events . Ben Matone Director-Investor Relations, Inovio Pharmaceuticals, Inc. Ben Matone-- Senior Director, Investor Relations Thank you, operator. INOVIO to Present at Upcoming Investor Conferences in September PR Newswire (US) - 9/1/2021 8:00:00 AM INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800 PR Newswire (US) - 8/26/2021 8:00:00 AM PLYMOUTH MEETING, Pa., March 4, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced that Dr. J. Joseph Kim, President and CEO, along with other members of INOVIO management, will present at the following investor conferences in March: NIO Inc. is a pioneer in China's premium electric vehicle . PLYMOUTH MEETING, Pa., March 4, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from . Why Investors Didn't Like Inovio's Seemingly Positive Clinical Results. Find the latest SEC Filings data for Inovio Pharmaceuticals, Inc. Common Stock (INO) at Nasdaq.com. CONTACTS: Media: Jeff Richardson, 267-440-4211, jrichardson@inovio.com Investors: Ben Matone, 484-362-0076, ben.matone@inovio.com 07/06/2021. World Vaccine Conference May 4 - 6 2021. Good day everybody and welcome to the INOVIO First Quarter 2020 Financial Results Conference Call. PLYMOUTH MEETING, Pa., Sept. 1, 2021-- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that Dr. J. Joseph Kim, President and CEO, will present at the following investor . Investor Relations Corporate Profile. PLYMOUTH MEETING, Pa., March 4, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market . For more information, visit www.inovio.com. For more information, visit www.inovio.com . For financial reporting, their fiscal year ends on December 31st. ET. Phase II results before end of June 2021 (end of Q2). INOVIO, a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, announced that Dr. J. Joseph Kim, President and CEO, will present at the following investor conferences in September:.
On March 4, 2021 INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, reported that Dr. J. Joseph Kim, President and CEO, along with other members of INOVIO management, will present at the following investor conferences in March (Press release, Inovio, MAR 4, 2021, View . Live and archived versions of the virtual presentations will be available through the INOVIO Investor Relations Events page and may be accessed by visiting INOVIO's website at https://ir.inovio . See the company profile for Inovio Pharmaceuticals, Inc. (INO) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives . By Keith Speights and Brian Orelli, PhD - Mar 11, 2021 at 7:08AM You're reading a free article with opinions that may . INOVIO also is a proud recipient of 2020 Women on Boards "W" designation recognizing companies with more than 20% women on their board of directors. Live and archived versions of the virtual presentations will be available through the INOVIO Investor Relations Events . Inovio Pharmaceuticals, Inc is primarely in the business of surgical & medical instruments & apparatus. 660 W. Germantown Pike, Suite 110 Plymouth Meeting, PA 19462 Phone: 267-440-4200 Fax: 267-440-4242 Investor Relations; Institutional Ownership and Shareholders . PLYMOUTH MEETING, Pa., Sept. 1, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that Dr. J. Joseph Kim, President and CEO, will present at the following investor conferences in September: Figure 7.
PLYMOUTH MEETING, Pa., Sept. 1, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced that Dr. J. Joseph Kim, President and CEO, along with other members of INOVIO management, will present at the following investor conferences in September: 07/27/2021.
A. DNA MEDICINES. PLYMOUTH MEETING, Pa., Sept. 1, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that Dr. J. Joseph Kim, President and CEO, will present at the following investor conferences in September: Date: Wednesday, September 23, 2020. 05/25/2021.
Investors: Ben Matone, Inovio, 484-362-0076 . PLYMOUTH MEETING, Pa., Sept. 1, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that Dr. J. Joseph Kim, President and CEO, will present at the following investor conferences in September: Evoqua Water Technologies Announces Upcoming Investor Events. INOVIO also is a proud recipient of 2020 Women on Boards "W" designation recognizing companies with more than 20% women on their board of directors. Dr. Kim is a great scientist, but he clearly has no idea how to run a business, as he has consistently overpromised and underdelivered since 2009.
September 1, 2021 - 8:00 am. Inovio Pharmaceuticals Inc (US:INO) has 382 institutional owners and shareholders (aka shareholding pattern) that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
INOVIO also is a proud recipient of 2020 Women on Boards "W" designation recognizing companies with more than 20% women on their board of directors. INOVIO to Present at Upcoming Investor Conferences in May PR Newswire PLYMOUTH MEETING, Pa., May 4, 2021 PLYMOUTH MEETING, Pa., May 4, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology . INOVIO to Present at Upcoming Investor Conferences in September PR Newswire (US) - 9/1/2021 8:00:00 AM INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800 PR Newswire (US) - 8/26/2021 8:00:00 AM Good afternoon, and thank you for joining the Inovio fourth quarter and year-end 2020 earnings conference call. Ben Matone.
VGX-3100 serves as the joint venture between Orient and INOVIO in the field of DNA immunotherapy. B. [Operator Instructions] I would now like to turn the conference call over to Ben Matone, Senior Director of Investor Relations. For more information, visit www.inovio.com. At the Vaccine Conference Inovio is up for Best Pharma Award (15). Investors: Ben Matone, 484-362-0076, ben.matone@inovio.com This press release contains certain forward-looking statements relating to our business, including our plans to develop and commercialize DNA medicines, our expectations regarding our research and development programs, PIPELINE. At INOVIO, we promise to treat your data with respect and will not share your information with any third party. Protective antibodies and killer T cells produced by immune system against diverse strains of a virus or cancer INOVIO DNA medicines power a patient's immune system to generate functional antibodies and killer T cells in vivo to fight cancer and infectious disease DNA . At the vaccine conference Inovio is up for best new vaccine technology/platform (15). Designed to evaluate safety, tolerability and immunogenicity of INO-4800 in a 2-dose regimen (1.0 mg or 2.0 mg), in a three-to-one randomization to receive either INO-4800 or placebo for each dose Clinical Development Strategy for INO-4800 INOVIO is a biotechnology company committed to powering a new way forward in DNA medicines to save and protect lives worldwide.